argenx NV ADR (ARGX)vsModerna Inc (MRNA)
ARGX
argenx NV ADR
$891.76
+1.05%
HEALTHCARE · Cap: $54.94B
MRNA
Moderna Inc
$214.17
+2.98%
HEALTHCARE · Cap: $87.04B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 166% more annual revenue ($5.92B vs $2.23B). ARGX leads profitability with a 31.7% profit margin vs -141.4%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+67.5%
Fair Value
$2566.94
Current Price
$891.76
$1675.18 discount
Margin of Safety
+69.9%
Fair Value
$134.71
Current Price
$214.16
$79.45 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 36.3%
Revenue surging 52.1% year-over-year
Earnings expanding 50.6% YoY
Conservative balance sheet, low leverage
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 165.8x book value
Trading at 12.6x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.7% and operating margin at 36.3%. Revenue growth of 52.1% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
ARGX profiles as a growth stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.09 — expect wider price swings.
ARGX is growing revenue faster at 52.1% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (73/100 vs 21/100), backed by strong 31.7% margins and 52.1% revenue growth. MRNA offers better value entry with a 69.9% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?